Revascularization Strategies in Patients with Coronary Artery Disease and Chronic Obstructive Lung Disease.

IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Treatment Options in Cardiovascular Medicine Pub Date : 2023-06-05 DOI:10.1007/s11936-023-00993-6

Matthew Brandorff, Julia Graham, Kirana Gudi

{"title":"Revascularization Strategies in Patients with Coronary Artery Disease and Chronic Obstructive Lung Disease.","authors":"Matthew Brandorff, Julia Graham, Kirana Gudi","doi":"10.1007/s11936-023-00993-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: This paper assesses recent literature on the impact of chronic obstructive pulmonary disease (COPD) in patients with coronary artery disease (CAD) undergoing revascularization. Specifically, to determine if there is an optimal revascularization strategy for this patient population, and if there are other modalities to assess the risks.Recent findings: There are limited new data in the last year addressing this clinical question. Recently there have been a series of studies which reinforced that COPD is a key independent risk factor for adverse outcomes after revascularization. There is no optimal revascularization strategy; however, there was a nonsignificant signal of potential benefit with percutaneous coronary intervention (PCI) with short-term outcomes in the SYNTAXES trial. Currently, pulmonary function tests (PFT) are limited in clarifying risk assessments prior to revascularization, and there are investigations into the use of biomarkers to provide further insight into this increased risk of adverse outcomes in patients with COPD.Summary: COPD is a key risk factor for poor outcomes in patients requiring revascularization. More investigations are needed to determine the optimum revascularization strategy.","PeriodicalId":35912,"journal":{"name":"Current Treatment Options in Cardiovascular Medicine","volume":" ","pages":"1-9"},"PeriodicalIF":0.8000,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239707/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Cardiovascular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11936-023-00993-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This paper assesses recent literature on the impact of chronic obstructive pulmonary disease (COPD) in patients with coronary artery disease (CAD) undergoing revascularization. Specifically, to determine if there is an optimal revascularization strategy for this patient population, and if there are other modalities to assess the risks.

Recent findings: There are limited new data in the last year addressing this clinical question. Recently there have been a series of studies which reinforced that COPD is a key independent risk factor for adverse outcomes after revascularization. There is no optimal revascularization strategy; however, there was a nonsignificant signal of potential benefit with percutaneous coronary intervention (PCI) with short-term outcomes in the SYNTAXES trial. Currently, pulmonary function tests (PFT) are limited in clarifying risk assessments prior to revascularization, and there are investigations into the use of biomarkers to provide further insight into this increased risk of adverse outcomes in patients with COPD.

Summary: COPD is a key risk factor for poor outcomes in patients requiring revascularization. More investigations are needed to determine the optimum revascularization strategy.

查看原文本刊更多论文

冠状动脉疾病和慢性阻塞性肺病患者的血运重建策略。

综述目的：本文评估了最近关于慢性阻塞性肺病（COPD）对冠状动脉疾病（CAD）患者进行血运重建的影响的文献。具体来说，确定是否有针对该患者群体的最佳血运重建策略，以及是否有其他方式来评估风险。最近的发现：在过去的一年中，解决这一临床问题的新数据有限。最近有一系列研究表明，COPD是血运重建后不良反应的一个关键的独立风险因素。没有最佳的血运重建策略；然而，在SYNTAXES试验中，经皮冠状动脉介入治疗（PCI）具有短期疗效的潜在益处的信号并不显著。目前，肺功能测试（PFT）在阐明血运重建前的风险评估方面受到限制，并且有研究使用生物标志物来进一步了解COPD患者不良后果风险的增加。总结：COPD是需要血运重建的患者不良后果的关键风险因素。需要更多的研究来确定最佳的血运重建策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published treatment-related advances in cardiovascular medicine. By providing clear, insightful, balanced contributions by international experts, the journal intends to elucidate novel approaches to treatment in those affected by the spectrum of cardiovascular-related diseases and conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as coronary artery disease, cerebrovascular disease and stroke, heart failure, pediatric and congenital heart disease, and valvular, myocardial, pericardial, and cardiopulmonary diseases. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known figures in the field, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.